- One of the worldwide actors in the area of injectable medical devices based on biopolymer transformation
- Creation: March 2003
- CEO: Gilles Bos
- Activity sectors: ophthalmology, orthopaedics and aesthetic dermatology
- Present in over 90 countries in aesthetic dermatology
- Three subsidiaries: in France, Germany and Japan
- Total staff: 150 employees
- A licensing agreement with the German group: Merz Pharmaceutical
- Four patents filed in the biopolymer transformation field
- 15% of annual revenue dedicated to research and development
- 2 laboratories
- Exponential sales
recommendprint this page top
